Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · see citing works

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391 · see citing works

Mutational Processes Molding the Genomes of 21 Breast Cancers

Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · see citing works

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

Beroukhim, R., Getz, G. A., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H. Y., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,055 · see citing works

PyClone: statistical inference of clonal population structure in cancer

Roth, A. J. L., Khattra, J. S., Yap, D., Wan, A. N. C., Laks, E., Biele, J., Ha, G., Aparicio, S. A. J. R., Bouchard‐Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 1,002 · see citing works

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 818 · see citing works

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752 · see citing works

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

Popova, T. G., Manié, É., Rieunier, G., Caux‐Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal‐Zafrani, B., Bollet, M. A., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 666 · see citing works

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works

IntOGen-mutations identifies cancer drivers across tumor types

González-Pérez, A., Perez-Llamas, C., Deu-Pons, J., Tamborero, D., Schroeder, M. P., Jené-Sanz, A., Santos, A., & López-Bigas, N. (2013) · Nature Methods · doi:10.1038/nmeth.2642 · Cited by 570 · see citing works

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481 · see citing works

PTEN: a new guardian of the genome

Yin, Y., & Shen, W. H. (2008) · Oncogene · doi:10.1038/onc.2008.241 · Cited by 386 · see citing works

Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography

Thompson, L. H. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.06.002 · Cited by 357 · see citing works

Association Between Osteosarcoma and Deleterious Mutations in the RECQL4 Gene in Rothmund-Thomson Syndrome

Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338 · see citing works

SomaticSignatures: inferring mutational signatures from single-nucleotide variants

Gehring, J. S., Fischer, B., Lawrence, M. F., & Huber, W. K. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv408 · Cited by 307 · see citing works

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Weston, V., Oldreive, C., Skowrońska, A., Oscier, D. G., Pratt, G., Dyer, M. J. S., Smith, G. C. M., Powell, J. E., Rudzki, Z., Kearns, P. R., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265769 · Cited by 300 · see citing works

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270 · see citing works

Etiology of Osteosarcoma

Fuchs, B., & Pritchard, D. J. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200204000-00007 · Cited by 246 · see citing works

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P., Timms, K. M., Abkevich, V., Schackmann, E. A., Wapnir, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0085 · Cited by 233 · see citing works

The Fanconi Anemia DNA Repair Pathway: Structural and Functional Insights into a Complex Disorder

Walden, H., & Deans, A. J. (2014) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-051013-022737 · Cited by 229 · see citing works

DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders

Mohaghegh, P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.741 · Cited by 228 · see citing works

Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer

Tavtigian, S. V., Oefner, P. J., Babikyan, D., Hartmann, A., Healey, S. C., Calvez‐Kelm, F. L., Lesueur, F., Byrnes, G. B., Chuang, S., Forey, N., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.08.018 · Cited by 192 · see citing works

Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility

Johnson, N., Fletcher, O., Palles, C., Rudd, M. F., Webb, E. L., Sellick, G. S., dos‐Santos‐Silva, I., McCormack, V., Gibson, L., Fraser, A., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm050 · Cited by 124 · see citing works

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R. G., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2572 · Cited by 121 · see citing works

Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach

Scott, M. C., Sarver, A. L., Gavin, K., Thayanithy, V., Getzy, D. M., Newman, R. A., Cutter, G., Lindblad‐Toh, K., Kisseberth, W. C., Hunter, L., et al. (2011) · Bone · doi:10.1016/j.bone.2011.05.008 · Cited by 121 · see citing works

IntOGen: integration and data mining of multidimensional oncogenomic data

Gundem, G., Perez-Llamas, C., Jené-Sanz, A., Kedzierska, A., Islam, A. B. M. M. K., Deu-Pons, J., Furney, S. J., & López-Bigas, N. (2010) · Nature Methods · doi:10.1038/nmeth0210-92 · Cited by 112 · see citing works

Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas

Joseph, C. G., Hwang, H., Jiao, Y., Wood, L. D., Kinde, I., Wu, J., Mandahl, N., Luo, J., Hruban, R. H., Diaz, L. A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22114 · Cited by 109 · see citing works

Characterization of FGFRL1, a Novel Fibroblast Growth Factor (FGF) Receptor Preferentially Expressed in Skeletal Tissues*

Trueb, B., Zhuang, L., Taeschler, S., & Wiedemann, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300281200 · Cited by 88 · see citing works

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome

Ribi, S., Baumhoer, D., Lee, K., Edison, Teo, A. S. M., Madan, B., Zhang, K., Kohlmann, W. K., Yao, F., Lee, W. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3115 · Cited by 77 · see citing works

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Smith, M. A., Hampton, O. A., Reynolds, C. P., Kang, M. H., Maris, J. M., Gorlick, R. G., Kolb, E. A., Lock, R. B., Carol, H., Keir, S. T., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25201 · Cited by 74 · see citing works

Chromosomal Instability in MYH - and APC -Mutant Adenomatous Polyps

Cardoso, J., Molenaar, L., de Menezes, R. X., van Leerdam, M. E., Rosenberg, C., Möslein, G., Sampson, J. R., Morreau, H. M., Boer, J. M., & Fodde, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2407 · Cited by 69 · see citing works

NuMA promotes homologous recombination repair by regulating the accumulation of the ISWI ATPase SNF2h at DNA breaks

Vidi, P., Liu, J., Salles, D. C., Jayaraman, S., Dorfman, G., Gray, M., Abad, P. C., Moghe, P. V., Irudayaraj, J., Wiesmüller, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku296 · Cited by 62 · see citing works

Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma

Mohseny, A. B., Tieken, C., van der Velden, P. A., Szuhai, K., de Andrea, C., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20817 · Cited by 59 · see citing works

Efficient Deletion of Normal Brca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy

Hay, T., Jenkins, H., Sansom, O. J., Martin, N. M. B., Smith, G. C. M., & Clarke, A. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1186 · Cited by 59 · see citing works

Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma

Martin, J. W., Chilton‐MacNeill, S., Koti, M., van Wijnen, A. J., Squire, J. A., & Zieleńska, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095843 · Cited by 56 · see citing works

MicroRNA-22 Suppresses DNA Repair and Promotes Genomic Instability through Targeting of MDC1

Lee, J.-H., Park, S.-J., Jeong, S.-Y., Kim, M.-J., Jun, S., Lee, H.-S., Chang, I. Y., Lim, S., Yoon, S. P., Yong, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2783 · Cited by 52 · see citing works

RECQ DNA Helicases and Osteosarcoma

Lu, L., Jin, W., Liu, H., & Wang, L. L. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_7 · Cited by 45 · see citing works

SomaticSignatures: Inferring Mutational Signatures from Single Nucleotide VariantsPreprint

Gehring, J. S., Fischer, B. M., Lawrence, M., et al. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/010686 · Cited by 27 · see citing works

A Case of Werner's Syndrome Associated with Osteosarcoma

Murata, K., Hatamochi, A., Shinkai, H., Ishikawa, Y., Kawaguchi, N., & Goto, M. (1999) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1999.tb02072.x · Cited by 14 · see citing works

The landscape of genomic alterations across childhood cancers

ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572 · see citing works

Advancing therapy for osteosarcoma

Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876 · see citing works

New Horizons in the Treatment of Osteosarcoma

Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem

Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 475 · see citing works

Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy

Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 470 · see citing works

The 2020 WHO Classification of Tumors of Bone: An Updated Review

Choi, J. H., & Ro, J. Y. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000293 · Cited by 405 · see citing works

Molecular Biology of Osteosarcoma

Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343 · see citing works

Sarcoma treatment in the era of molecular medicine

Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319 · see citing works

Cancer stem cells in osteosarcoma

Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303 · see citing works

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 289 · see citing works

Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy

Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280 · see citing works

DNA Damage Follows Repair Factor Depletion and Portends Genome Variation in Cancer Cells after Pore Migration

Irianto, J., Xia, Y., Pfeifer, C. R., Athirasala, A., Ji, J., Alvey, C. M., Tewari, M., Bennett, R. R., Harding, S. M., Liu, A. J., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.11.049 · Cited by 280 · see citing works

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261 · see citing works

Pharmacological basis and new insights of taxifolin: A comprehensive review

Das, A., Baidya, R., Chakraborty, T., Samanta, A. K., & Roy, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112004 · Cited by 253 · see citing works

Molecular genetics of osteosarcoma

Rickel, K., Fang, F., & Tao, J. (2016) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 244 · see citing works

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma

Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0197 · Cited by 243 · see citing works

Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma

Kager, L., Tamamyan, G., & Bielack, S. (2016) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 240 · see citing works

Osteosarcoma: Accelerating Progress Makes for a Hopeful Future

Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237 · see citing works

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233 · see citing works

Osteosarcoma: Cells‐of‐Origin, Cancer Stem Cells, and Targeted Therapies

Abarrategi, A., Tornín, J., Martínez-Cruzado, L., Hamilton, A., Martínez‐Campos, E., Rodrigo, J. P., González, M. V., Baldini, N., Garcı́a-Castro, J., & Rodrı́guez, R. (2016) · Stem Cells International · doi:10.1155/2016/3631764 · Cited by 211 · see citing works

Improving human cancer therapy through the evaluation of pet dogs

LeBlanc, A. K., & Mazcko, C. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0297-3 · Cited by 202 · see citing works

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Tellez-Gabriel, M., Ory, B., Lamoureux, F., Heymann, M., & Heymann, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122142 · Cited by 193 · see citing works

Magnetic Hyperthermia–Synergistic H2O2 Self‐Sufficient Catalytic Suppression of Osteosarcoma with Enhanced Bone‐Regeneration Bioactivity by 3D‐Printing Composite Scaffolds

Dong, S., Chen, Y., Yu, L., Lin, K., & Wang, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201907071 · Cited by 181 · see citing works

Biology of Bone Sarcomas and New Therapeutic Developments

Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163 · see citing works

A first-generation pediatric cancer dependency map

Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153 · see citing works

Advances in the management of osteosarcoma

Bielack, S., Hecker‐Nolting, S., Blattmann, C., & Kager, L. (2016) · F1000Research · doi:10.12688/f1000research.9465.1 · Cited by 152 · see citing works

LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis

Shen, Y., Xu, J., Pan, X., Zhang, Y., Weng, Y., Zhou, D., & He, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2485-1 · Cited by 150 · see citing works

Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases

Wang, D., Niu, X., Wang, Z., Song, C., Huang, Z., Chen, K., Duan, J., Bai, H., Xu, J., Zhao, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1086 · Cited by 148 · see citing works

Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment

Jiang, Y., Wang, J., Sun, M., Zuo, D., Wang, H., Shen, J., Jiang, W., Mu, H., Ma, X., Yin, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34689-5 · Cited by 148 · see citing works

Advances in Osteosarcoma

Panez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 132 · see citing works

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127 · see citing works

SFPQ and NONO suppress RNA:DNA-hybrid-related telomere instability

Petti, E., Buemi, V., Zappone, A., Schillaci, O., Broccia, P. V., Dinami, R., Matteoni, S., Benetti, R., & Schoeftner, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08863-1 · Cited by 123 · see citing works

The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations

Villani, A., Davidson, S., Kanwar, N., Lo, W. W., Li, Y., Cohen‐Gogo, S., Fuligni, F., Edward, L.-M., Light, N. D., Layeghifard, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00474-y · Cited by 121 · see citing works

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

Gardner, H. L., Sivaprakasam, K., Briones, N., Zismann, V., Perdigones, N., Drenner, K., Facista, S., Richholt, R., Liang, W., Aldrich, J., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0487-2 · Cited by 120 · see citing works

Correlation AnalyzeR: functional predictions from gene co-expression correlations

Miller, H. E., & Bishop, A. J. R. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04130-7 · Cited by 116 · see citing works

Molecular mechanisms underpinning sarcomas and implications for current and future therapy

Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 114 · see citing works

Biology and pathogenesis of human osteosarcoma (Review)

de Azevedo, J., Fernandes, T. A. A. D. M., Fernandes, J. V., de Azevedo, J. C. V., Lanza, D. C. F., Bezerra, C. M., Andrade, V., de Ara�jo, J., & Fernandes, J. V. (2019) · Oncology Letters · doi:10.3892/ol.2019.11229 · Cited by 112 · see citing works

Targeted therapy for osteosarcoma: a review

Li, S., Zhang, H., Liu, J., & Shang, G. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04614-4 · Cited by 105 · see citing works

Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution

Valle-Inclán, J. E., Noon, S. D., Trevers, K. E., Elrick, H., van Belzen, I. A. E. M., Zumalave, S., Sauer, C. M., Tanguy, M., Butters, T., Muyas, F., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.005 · Cited by 100 · see citing works

Genome‐wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma

Smida, J., Xu, H., Zhang, Y., Baumhoer, D., Ribi, S., Kovac, M. B., von Luettichau, I., Bielack, S., O’Leary, V. B., Leib‐Mösch, C., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30778 · Cited by 98 · see citing works

Tumor cell membrane-camouflaged responsive nanoparticles enable MRI-guided immuno-chemodynamic therapy of orthotopic osteosarcoma

Fu, L., Zhang, W., Zhou, X., Fu, J., & He, C. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.035 · Cited by 98 · see citing works

An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing

Baumhoer, D., Amary, F. M., & Flanagan, A. M. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22699 · Cited by 96 · see citing works

Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers

Thatikonda, V., Islam, S. M. A., Autry, R. J., Jones, B. C., Gröbner, S. N., Warsow, G., Hutter, B., Hüebschmann, D., Fröhling, S., Kool, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00509-4 · Cited by 95 · see citing works

PTEN in osteosarcoma: Recent advances and the therapeutic potential

Zheng, C., Tang, F., Min, L., Hornicek, F. J., Duan, Z., & Tu, C. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188405 · Cited by 92 · see citing works

SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma

Sakthikumar, S., Elvers, I., Kim, J., Arendt, M. L., Thomas, R. J., Turner-Maier, J., Swofford, R., Johnson, J., Schumacher, S. E., Alföldi, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3558 · Cited by 90 · see citing works

Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy

Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 90 · see citing works

SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT–receptor complex

Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89 · see citing works

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Park, H. J., Bae, J. S., Kim, K. M., Moon, Y. J., Park, S., Ha, S. H., Hussein, U. K., Zhang, Z., Park, H. S., Park, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0772-9 · Cited by 89 · see citing works

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

Engert, F., Kovac, M. B., Baumhoer, D., Nathrath, M., & Fulda, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10720 · Cited by 87 · see citing works

Advances in targeted therapy for osteosarcoma based on molecular classification

Chen, Y., Liu, R., Wang, W., Wang, C., Zhang, N., Shao, X., He, Q., & Ying, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105684 · Cited by 86 · see citing works

An overview of resistance to chemotherapy in osteosarcoma and future perspectives

García-Ortega, D. Y., Cabrera-Nieto, S. A., Caro-Sánchez, C. H. S., & Cruz‐Ramos, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.18 · Cited by 86 · see citing works

Canine sarcomas as a surrogate for the human disease

Gustafson, D. L., Duval, D. L., Regan, D. P., & Thamm, D. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.012 · Cited by 85 · see citing works

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma

Paramasivam, N., Hübschmann, D., Toprak, U. H., Ishaque, N., Neidert, M. C., Schrimpf, D., Stichel, D., Reuß, D., Sievers, P., Reinhardt, A., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02008-w · Cited by 83 · see citing works

Origin and Therapies of Osteosarcoma

Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 83 · see citing works

Current Status and Prospects of Clinical Treatment of Osteosarcoma

Jiang, Z.-Y., Liu, J., Wang, X., Ma, Y., & Fu, D. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221124696 · Cited by 78 · see citing works

Current Status and Prospects of Targeted Therapy for Osteosarcoma

Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 73 · see citing works

Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases

Koelsche, C., Schrimpf, D., Tharun, L., Roth, E. K., Sturm, D., Jones, D., Renker, E.-K., Sill, M., Baude, A., Sahm, F., et al. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0075-5 · Cited by 73 · see citing works

Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait HallmarksPreprint

Fortunato, A., Boddy, A., Mallo, D., Aktipis, A., Maley, C. C., & Pepper, J. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029652 · Cited by 72 · see citing works

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Fang, F., VanCleave, A. M., Helmuth, R., de Oliveira, H. T., Rickel, K., Wollenzien, H., Sun, H., Zeng, E., Zhao, J., & Tao, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26377 · Cited by 71 · see citing works

Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription

Chen, F., Mo, J., & Zhang, L. (2016) · Tumor Biology · doi:10.1007/s13277-016-5256-y · Cited by 70 · see citing works

Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma

Wang, L., Huang, X., You, X., Yi, T., Lu, B., Liu, J., Lu, G., Ma, M., Zou, C., Wu, J., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00248-x · Cited by 70 · see citing works

A novel multifunctional carbon aerogel-coated platform for osteosarcoma therapy and enhanced bone regeneration

Dong, S., Zhang, Y., Wan, J., Cui, R., Yu, X., Zhao, G., & Lin, K. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb02383f · Cited by 66 · see citing works

Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration

Pfeifer, C. R., Alvey, C. M., Irianto, J., & Discher, D. E. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.04.005 · Cited by 64 · see citing works

Analysis of mutational signatures with yet another package for signature analysis

Hübschmann, D., Jopp‐Saile, L., Andresen, C., Krämer, S., Gu, Z., Heilig, C. E., Kreutzfeldt, S., Teleanu, V., Fröhling, S., Eils, R., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22918 · Cited by 63 · see citing works

TP53 in Biology and Treatment of Osteosarcoma

Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 63 · see citing works

Chemotherapy for Bone Sarcoma in Adults

Wagner, M. J., Livingston, J. A., PATEL, S. R., & Benjamin, R. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009944 · Cited by 62 · see citing works

Drugs in early clinical development for the treatment of osteosarcoma

Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 62 · see citing works

Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2

Hartford, S. A., Chittela, R. K., Ding, X., Vyas, A., Martin, B. K., Burkett, S. S., Haines, D. C., Southon, E. A., Tessarollo, L., & Sharan, S. K. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006236 · Cited by 60 · see citing works

Genomics and the Immune Landscape of Osteosarcoma

Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58 · see citing works

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment

Raimondi, L., Luca, A. D., Costa, V., Amodio, N., Carina, V., Bellavia, D., Tassone, P., Pagani, S., Fini, M., Alessandro, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19852 · Cited by 56 · see citing works

Clonal dynamics in osteosarcoma defined by RGB marking

Gambera, S., Abarrategi, A., González‐Camacho, F., Morales‐Molina, Á., Roma, J. M., Alfranca, A., & Garcı́a-Castro, J. (2018) · Nature Communications · doi:10.1038/s41467-018-06401-z · Cited by 56 · see citing works

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma

Cheng, L., Pandya, P. H., Liu, E., Chandra, P., Wang, L., Murray, M. E., Carter, J., Ferguson, M. J., Saadatzadeh, M. R., Bijangi‐Vishehsaraei, K., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-018-0456-5 · Cited by 55 · see citing works

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma

Evdokimova, V. E., Gassmann, H., Radvanyi, L. G., & Burdach, S. E. G. (2022) · Cancers · doi:10.3390/cancers15010272 · Cited by 54 · see citing works

Whole-exome analysis in osteosarcoma to identify a personalized therapy

Chiappetta, C., Mancini, M., Lessi, F., Aretini, P., Gregorio, V. D., Puggioni, C., Carletti, R., Petrozza, V., Civita, P., Franceschi, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19010 · Cited by 54 · see citing works

The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells

Schiavone, K., Garnier, D., Heymann, M., & Heymann, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14366-4_11 · Cited by 54 · see citing works

The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment

Brady, S. W., Ma, X., Bahrami, A., Satas, G., Wu, G., Newman, S., Rusch, M., Putnam, D. K., Mulder, H. L., Yergeau, D. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0620 · Cited by 52 · see citing works

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Zoumpoulidou, G., Alvarez-Mendoza, C., Mancusi, C., Ahmed, R.-M., Denman, M., Steele, C. D., Tarabichi, M., Roy, E., Davies, L. R., Manji, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27291-8 · Cited by 51 · see citing works

G enetic and clonal dissection of osteosarcoma progression and lung metastasis

Xu, H., Zhu, X., Bao, H., Shek, T. W., Huang, Z., Wang, Y., Wu, X., Wu, Y., Chang, Z., Wu, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31389 · Cited by 51 · see citing works

Precision medicine in pediatric oncology

Burdach, S. E. G., Westhoff, M., Steinhauser, M., & Debatin, K. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0084-3 · Cited by 51 · see citing works

Current questions in bone sarcomas

Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49 · see citing works

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity

Basu-Roy, U., Han, E. J., Rattanakorn, K., Gadi, A., Verma, N., Maurizi, G., Gunaratne, P. H., Coarfa, C., Kennedy, O. D., Garabedian, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11273 · Cited by 48 · see citing works

Computational approaches for discovery of mutational signatures in cancer

Baez‐Ortega, A., & Gori, K. C. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx082 · Cited by 48 · see citing works

Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma

Negri, G. L., Grande, B. M., Delaidelli, A., El-Naggar, A. M., Cochrane, D. R., Lau, C. C., Triche, T. J., Moore, R. A., Jones, S. J. M., Montpetit, A., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5319 · Cited by 48 · see citing works

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Zhou, Q., Howard, M. E., Tu, X., Zhu, Q., Denbeigh, J. M., Remmes, N. B., Herman, M., Beltran, C. J., Yuan, J., Greipp, P. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2960 · Cited by 48 · see citing works

Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas

Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48 · see citing works

Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma

Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46 · see citing works

Comparative Immunology and Immunotherapy of Canine Osteosarcoma

Mason, N. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_14 · Cited by 46 · see citing works

In vitro three-dimensional cell cultures for bone sarcomas

Muñoz-García, J., Jubelin, C., Loussouarn, A., Goumard, M., Griscom, L., Renodon‐Cornière, A., Heymann, M., & Heymann, D. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100379 · Cited by 45 · see citing works

What’s new in bone forming tumours of the skeleton?

Franceschini, N., Lam, S. W., Cleton-Jansen, A., & Bovée, J. V. M. G. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02683-w · Cited by 44 · see citing works

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma

Oehl, K., Vrugt, B., Wagner, U., Kirschner, M. B., Meerang, M., Weder, W., Felley‐Bosco, E., Wollscheid, B., Bankov, K., Demes, M. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4037 · Cited by 44 · see citing works

ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

Hingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., Teicher, B., Erickson, S., Gatto, G., Smith, M. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0406 · Cited by 41 · see citing works

LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway

Han, W., & Liu, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.014 · Cited by 41 · see citing works

Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis

Marchais, A., Costa, M. E. M. D., Job, B., Abbas, R., Drubay, D., Piperno‐Neumann, S., Fromigué, O., Gomez‐Brouchet, A., Rédiní, F., Droit, R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-20-4189 · Cited by 41 · see citing works

DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications

Sadoughi, F., Dana, P. M., Asemi, Z., & Yousefi, B. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103105 · Cited by 40 · see citing works

Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma

Marinoff, A. E., Spurr, L. F., Fong, C., Li, Y. Y., Forrest, S. J., Ward, A., Doan, D., Corson, L., Mauguen, A., Pinto, N. R., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00334 · Cited by 39 · see citing works

Profiling targetable immune checkpoints in osteosarcoma

McEachron, T. A., Triche, T. J., Sorenson, L., Parham, D. M., & Carpten, J. D. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1475873 · Cited by 39 · see citing works

Homologous recombination repair deficiency as a therapeutic target in sarcoma

Oza, J. H., Doshi, S. D., Hao, L. Y., Musi, E., Schwartz, G. K., & Ingham, M. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.10.002 · Cited by 39 · see citing works

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT

de Nonneville, A. T., Salas, S., Bertucci, F., Sobinoff, A. P., Adélaı̈de, J., Guillé, A., Finetti, P., Noble, J. R., Churikov, D., Chaffanet, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215859 · Cited by 39 · see citing works

Abstract 1634: BRCA-like phenotype constitutes hallmark of osteosarcoma

Kovac, M. B., Ribi, S., Blattmann, C., Nathrath, M., & Baumhoer, D. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1634

Die klonale Evolution des Osteosarkoms

Baumhoer, D. (2016) · Der Pathologe · doi:10.1007/s00292-016-0200-x · Cited by 2 · see citing works

Abstract A06: BRCA-like phenotype as a hallmark of osteosarcoma's converging evolution

Kovac, M. B., Ribi, S., Blattmann, C., Nathrath, M., & Baumhoer, D. (2018) · Clinical Cancer Research · doi:10.1158/1557-3265.sarcomas17-a06

Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma

Chi, X., Ji, T., Li, J., Xu, J. H., Tang, X., Xie, L., Meng, F., & Guo, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s317809 · Cited by 4 · see citing works

Whole exome sequencing of a single osteosarcoma case¿integrative analysis with whole transcriptome RNA-seq data

Reimann, E., Kõks, S., Ho, X. D., Maasalu, K., & Märtson, A. (2014) · Human Genomics · doi:10.1186/s40246-014-0020-0 · Cited by 79 · see citing works